| CRISPR Medicine | This is an overview of articles related to blood disorders
Minutes ago, French and Italian researchers published a gene-editing strategy using adenine base editors to precisely repair two of the most common...
SNIPR Biome has dosed the first patient in its Phase 1b trial of SNIPR001, a CRISPR-CAS-armed bacteriophage therapy that represents a new frontier in...
Located in the ETH Innovation & Entrepreneurship Lab in Zürich (Switzerland), Ariya Bio's goal is to develop safe and effective gene-editing therapies...
There are currently four clinical-stage gene-editing candidates in clinical trials for sickle cell disease, which affects millions of people worldwide...
Editas Medicine recently announced positive initial safety and efficacy data for its CRISPR-edited cell therapy EDIT-301. The data was obtained from...
In this clinical update, we look at recent advances in two clinical-stage gene-editing programmes. Editas Medicine's sickle cell disease candidate...
In our first clinical update of 2022, we look at three new IND approvals for gene-edited therapies for life-threatening E. coli infections,...
In 2021, we've seen positive clinical data for the first ever in vivo CRISPR medicines, base editors are heading for the clinic, and CRISPR therapies...
